Aurobindo Pharma报告,Q1净利润增加61%,达到919卢比,美国市场收入增加13.3%。 Aurobindo Pharma reports a 61% YoY increase in Q1 net profit to Rs 919 crore and a 13.3% rise in US market revenue.

Aurobindo Pharma报告说,从Q1净利润增加到919卢比的利润增加了61%,上一季度从6,851卢比的营业收入增加到7,567卢比。 Aurobindo Pharma reports 61% YoY increase in Q1 net profit to Rs 919 crore, with revenue from operations rising to Rs 7,567 crore from Rs 6,851 crore in the previous year's quarter. 美国市场贡献了合并收入的47%,收入增加了13.3%,达到3 555卢比。 US market contributes 47% of consolidated revenue, with a 13.3% increase in revenue to Rs 3,555 crore. Aurobindo Pharma在季度期间向美国林业发展局提交了8份ANDA申请,并获得10份ANDA的最后批准,包括一份专门产品。 Aurobindo Pharma filed 8 ANDA applications with the US FDA during the quarter and received final approval for 10 ANDAs, including one specialty product.